Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humana Medicare Advantage Plans Targeting Hemlibra, Herceptin Hylecta With Step Therapy

Executive Summary

Fail first requirements for 2020 also target drugs for myelodysplastic syndrome and chronic obstructive pulmonary disease, building on the step therapy program launched by Humana in 2019.

You may also be interested in...



Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key

Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.

Humana Jumps In: Medicare Part B Step Therapy Program Includes Cancer Drugs

Biopharma manufacturers view implementation of management tool in Medicare Advantage plans with concern, urge US Centers for Medicare and Medicaid Services to withdraw permission for use of step therapy for Part B drugs. 

Lecanemab Data On Benefit In Alzheimer’s Might Satisfy FDA – But What About Medicare?

Centers for Medicare and Medicaid Services’ standard for determining whether drugs produce a clinically meaningful improvement in cognition that would allow for broader Medicare coverage is unclear. But Eisai/Biogen’s lecanemab is likely to serve as a first test.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel